[Effect of D-dimer on the prognosis of patients with aneurysmal subarachnoid hemorrhage based on propensity score matching]
- PMID: 35927056
- DOI: 10.3760/cma.j.cn112137-20211123-02606
[Effect of D-dimer on the prognosis of patients with aneurysmal subarachnoid hemorrhage based on propensity score matching]
Abstract
Objective: To evaluate the effect of D-dimer on the prognosis of patients with aneurysmal subarachnoid hemorrhage (aSAH). Methods: A total of 1 658 patients who were first diagnosed with aSAH in West China Hospital of Sichuan University from December 2013 to June 2019 were retrospectively analyzed. All patients were divided into four groups according to the median and quartiles of D-dimer level, including 415 cases, 414 cases, 414 cases, and 415 cases in groups Q1, Q2, Q3, and Q4, respectively. Groups Q2, Q3, Q4, and group Q1 were matched by propensity score matching (PSM), and the correlation between D-dimer and each outcome was analyzed by logistic regression. Since there is no general clinical classification standard for D-dimer, this study attempted to reclassify patients into groups q1 (<0.55 mg/L, 94 cases), q2 (0.55-1.65 mg/L, 435 cases), q3 (1.65-5.50 mg/L, 650 cases) and q4 (>5.50 mg/L, 303 cases) based on 1, 3, 5, 10 times of the upper limit of the current clinical reference value. Results: The age of 1 658 aSAH patients were (57±12) years, including 1 068 males and 590 females. After PSM based on the median and quartiles of D-dimer level, there were 318 cases, 318 cases, 251 cases, and 229 cases in groups Q1, Q2, Q3, and Q4, respectively. Compared with group Q1 (<1.23 mg/L), the risk of in-hospital infection (OR=2.14, 95%CI: 1.47-3.11, P<0.001), pneumonia (OR=2.22, 95%CI: 1.51-3.28, P<0.001), urinary tract infection (OR=1.75, 95%CI: 1.12-2.75, P=0.014) and intracranial rebleeding (OR=3.59, 95%CI: 1.30-9.91, P=0.013) group Q4 (>4.95 mg/L) was higher. Likewise, the risk of adverse outcomes in group Q4 was also higher than that in group Q1, including unfavorable outcome at discharge (OR=2.12, 95%CI: 1.43-3.14, P<0.001), mortality during hospitalization (OR=3.03, 95%CI: 1.26-7.33, P=0.014), mortality within 90 days (OR=2.33, 95%CI:1.29-4.22, P=0.005), mortality within 180 days (OR=1.92, 95%CI: 1.12-3.29, P=0.018), mortality within 1 year (OR=2.07, 95%CI:1.23-3.47, P=0.006) and mortality during the longest follow-up period (OR=1.97, 95%CI:1.26-3.09, P=0.003). After secondary grouping and PSM based on current clinical reference values, there were 90 cases, 87 cases, 90 cases, and 43 cases, respectively in groups q1, q2, q3 and q4. The risk of nosocomial infection (OR=2.26, 95%CI: 1.14-4.45, P=0.019), blood-borne infection (OR=8.86, 95%CI:1.08-72.78, P=0.042), poor prognosis at discharge (OR=4.92, 95%CI: 2.18-11.07, P<0.001), death within 180 days (OR=3.39, 95%CI: 1.04-11.08, P=0.043), death within 1 year (OR=3.23, 95%CI: 1.10-9.49, P=0.033), and death within the longest follow-up period (OR=3.28, 95%CI: 1.34-8.01, P=0.009) was still higher in group q4 than that in group q1. Conclusion: aSAH patients with high D-dimer level have a higher risk of complications and mortality during hospitalization and worse clinical prognosis.
目的: 评估D-二聚体对动脉瘤性蛛网膜下腔出血(aSAH)患者预后的影响。 方法: 回顾性分析2013年12月至2019年6月于四川大学华西医院被首次诊断为aSAH的患者资料,共1 658例,所有患者根据D-二聚体水平中位数和四分位数分为Q1~Q4 4组,分别为415例、414例、414例、415例。通过倾向性评分匹配法(PSM)对Q2、Q3、Q4和Q1分别进行匹配,采用logistic回归模型分析D-二聚体与各个结局的关联。由于目前临床尚无通用的D-二聚体分类标准,本研究尝试根据目前临床参考值上限的1、3、5、10倍将患者再次分为q1(<0.55 mg/L,94例)、q2(0.55~1.65 mg/L,435例)、q3(1.65~5.50 mg/L,650例)和q4(>5.50 mg/L,303例)4组,同样作PSM及logistic回归分析,以检验不同的D-二聚体分类方法下,D-二聚体是否仍然与aSAH预后相关。 结果: 1 658例aSAH患者年龄(57±12)岁,男1 068例,女590例。根据D-二聚体水平中位数和四分位数法分组PSM后,4组例数分别为318例、318例、251例、229例。Q4组(>4.95 mg/L)患者与Q1(<1.23 mg/L)组相比,Q4组患者院内感染(OR=2.14,95%CI:1.47~3.11,P<0.001);肺部感染(OR=2.22,95%CI:1.51~3.28,P<0.001)、尿道感染(OR=1.75,95%CI:1.12~2.75,P=0.014)以及颅内再出血(OR=3.59,95%CI:1.30~9.91,P=0.013)风险较高。Q4组患者发生不良预后结局的风险也高于Q1组,不良预后结局包括出院时预后不良(OR=2.12,95%CI:1.43~3.14,P<0.001);住院期间死亡(OR=3.03,95%CI:1.26~7.33,P=0.014);90 d内死亡(OR=2.33,95%CI:1.29~4.22,P=0.005);180 d内死亡(OR=1.92,95%CI:1.12~3.29,P=0.018);1年内死亡(OR=2.07,95%CI:1.23~3.47,P=0.006)以及最长随访期内死亡(OR=1.97,95%CI:1.26~3.09,P=0.003)。在根据目前临床参考值作二次分组并进行PSM后,4组例数分别为90例、87例、90例、43例。q4组患者的院内感染(OR=2.26,95%CI:1.14~4.45,P=0.019)、血行感染(OR=8.86,95%CI:1.08~72.78,P=0.042)、出院时预后不良(OR=4.92,95%CI:2.18~11.07,P<0.001)、180 d内死亡(OR=3.39,95%CI:1.04~11.08,P=0.043)、1年内死亡(OR=3.23,95%CI:1.10~9.49,P=0.033)以及最长随访期内死亡风险(OR=3.28,95%CI:1.34~8.01,P=0.009)仍然高于q1组患者。 结论: 高D-二聚体的aSAH患者住院期间并发症发生风险及病死率更高,临床预后更差。.
Similar articles
-
Relationship between De Ritis and clinical outcomes in patients with aneurysmal subarachnoid hemorrhage: Insights from the LongTEAM registry.Sci Rep. 2025 Apr 10;15(1):12314. doi: 10.1038/s41598-025-90843-1. Sci Rep. 2025. PMID: 40210942 Free PMC article.
-
Association between D-dimer levels and long-term mortality in patients with aneurysmal subarachnoid hemorrhage.Neurosurg Focus. 2022 Mar;52(3):E8. doi: 10.3171/2021.12.FOCUS21512. Neurosurg Focus. 2022. PMID: 35231898
-
Sex differences in the association between D-dimer and the incidence of acute kidney injury in patients admitted with ST-segment elevation myocardial infarction: a retrospective observational study.Intern Emerg Med. 2024 Jan;19(1):91-98. doi: 10.1007/s11739-023-03443-0. Epub 2023 Oct 14. Intern Emerg Med. 2024. PMID: 37837488
-
[Idiopathic subarachnoid hemorrhage; comparison of different bleeding patterns and long-term outcome].Neurocirugia (Astur). 2002 Apr;13(2):110-9. doi: 10.1016/s1130-1473(02)70630-1. Neurocirugia (Astur). 2002. PMID: 12058602 Review. Spanish.
-
D-Dimer and the Short-Term Prognosis of Patients with Subarachnoid Hemorrhage: A Meta-Analysis.Eur Neurol. 2024;87(4):188-202. doi: 10.1159/000540163. Epub 2024 Jul 18. Eur Neurol. 2024. PMID: 38991507
Cited by
-
Association between serum neuron-specific enolase at admission and the risk of delayed neuropsychiatric sequelae in adults with carbon monoxide poisoning: A meta-analysis.Biomol Biomed. 2024 Oct 17;24(6):1482-1490. doi: 10.17305/bb.2024.10757. Biomol Biomed. 2024. PMID: 38850112 Free PMC article.
MeSH terms
Substances
Grants and funding
- 2018YFA0108603, 2018YFA0108604/National Key R&D Program of China
- 2021HXFH014/The 1·3·5 Project for Disciplines of Excellence-Clinical Research Incubation Project, West China Hospital, Sichuan University
- 2019HXCX07/Innovation Project of Hospital-Enterprise Cooperation clinical Research of West China Hospital
LinkOut - more resources
Full Text Sources
Miscellaneous